CAJ | 학술논문

男性骨质疏松症（ male osteoporosis ）患病率逐年增加，但未被充分重视。目前被批准治疗男性骨质疏松的主要药物包括双膦酸盐、甲状旁腺素制剂、雄激素、人源性核因子κB 受体活化因子配基（ RANKL）特异性单克隆抗体等。正在研发的多种新药有望改善男性骨质疏松患者的骨强度及生活质量。本文就男性骨质疏松症的药物治疗进展进行综述，以期提高对本病的认识。
남성골질소송증（ male osteoporosis ）환병솔축년증가，단미피충분중시。목전피비준치료남성골질소송적주요약물포괄쌍련산염、갑상방선소제제、웅격소、인원성핵인자κB 수체활화인자배기（ RANKL）특이성단극륭항체등。정재연발적다충신약유망개선남성골질소송환자적골강도급생활질량。본문취남성골질소송증적약물치료진전진행종술，이기제고대본병적인식。
Male osteoporosis is a common but under-recognized disease with growing prevalence .Approved ther-apies to male osteoporosis include the bisphosphonates , parathyroid hormone , androgen and the monoclonal antibody against receptor activator of nuclear factor-kappa B ligand ( RANKL) .A good deal of new drugs are expected to improve the bone strength and the life quality of male osteoporosis .We review the treatment of male osteoporosis in order to im-prove the understanding of this disease .